SCHEMBL8327653

SCHEMBL8327653

CCN(CC)Cc1ccc(OC)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
KDM4E B2RXH2 1/20 0.59
MITF O75030 1/20 0.59
HTT P42858 1/20 0.59
ACHE P22303 2/20 0.52
MEP1B Q16820 1/20 0.52
HTR1A P08908 1/20 0.51
HTR2C P28335 1/20 0.51
HTR7 P34969 1/20 0.51
HTR2B P41595 1/20 0.51
HTR5A P47898 1/20 0.51
HTR6 P50406 1/20 0.51
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
BCHE P06276 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8324389 0.82 HTR7 (0.58) ALDH1A1KDM4EMITFHTTACHE
SCHEMBL186570 0.82 HTT (0.50) ALDH1A1KDM4EMITFHTT
SCHEMBL29442867 0.82 HTT (0.50) ALDH1A1KDM4EMITFHTT
SCHEMBL2759522 0.80 HTT (0.51) ALDH1A1KDM4EMITFHTT
SCHEMBL3436226 0.79 HTT (0.52) ALDH1A1KDM4EMITFHTTACHE
SCHEMBL16180726 0.79 ACHE (0.56) ACHEHTR1AHTR2CHTR7HTR2B
SCHEMBL14340525 0.79 KDM4E (0.52) ALDH1A1KDM4EMITFHTTACHE
Ammonia Solution, Strong SCHEMBL23291273 0.78 HTT (0.50) ALDH1A1KDM4EMITFHTT
SCHEMBL14924466 0.77 HTR7 (0.52) ALDH1A1ACHEHTR1AHTR2CHTR7
SCHEMBL19936609 0.77 KDM4E (0.50) ALDH1A1KDM4EMITFHTTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592426-B1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2007-12-19 EP disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 WO disclosed